[go: up one dir, main page]

PE20121085A1 - Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades - Google Patents

Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades

Info

Publication number
PE20121085A1
PE20121085A1 PE2012000076A PE2012000076A PE20121085A1 PE 20121085 A1 PE20121085 A1 PE 20121085A1 PE 2012000076 A PE2012000076 A PE 2012000076A PE 2012000076 A PE2012000076 A PE 2012000076A PE 20121085 A1 PE20121085 A1 PE 20121085A1
Authority
PE
Peru
Prior art keywords
estra
dien
pentafluoroethyl
hydroxy
treatment
Prior art date
Application number
PE2012000076A
Other languages
English (en)
Inventor
Wolfgang Schwede
Ulrich Klar
Carsten Moller
Andrea Rotgeri
Wilhelm Bone
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20121085A1 publication Critical patent/PE20121085A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 ES Y, FENILO MONO-O DISUSTITUIDO CON Y; Y ES SR2, S(O)R3, S(O)2R3, S(O)(NH)R3, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ARALQUILO C7-C10, ARILO; R3 ES ALQUILO C1-C6, ARILO; X ES O, NOH, NNHSO2H, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (11BETA,17BETA)-11-[4-(METILSULFANIL)FENIL]-17-(PENTAFLUOROETIL)ESTRA-4,9-DIEN-3-ONA; N-[{4-[(11BETA,17BETA)-17-HIDROXI-3-OXO-17-(PENTAFLUOROETIL)ESTRA-4,9-DIEN-11-IL]FENIL}(RS)(METIL)OXIDO-LAMBDA6-SULFANILIDEN]-4-METILBENCENSULFONAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE FIBROIDES UTERINOS, ENDOMETRIOSIS, MENINGIOMAS, TRASTORNOS ASOCIADOS CON LA MENOPAUSIA, ENTRE OTROS
PE2012000076A 2009-07-20 2010-07-07 Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades PE20121085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009034362A DE102009034362A1 (de) 2009-07-20 2009-07-20 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Publications (1)

Publication Number Publication Date
PE20121085A1 true PE20121085A1 (es) 2012-08-04

Family

ID=43383964

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002208A PE20170084A1 (es) 2009-07-20 2010-07-07 Derivados de 17-hidroxi-17-pentafluoroetil-estra-4-9(10)-dien-11-arilo como antagonistas de progesterona y procedimientos para su preparacion
PE2012000076A PE20121085A1 (es) 2009-07-20 2010-07-07 Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016002208A PE20170084A1 (es) 2009-07-20 2010-07-07 Derivados de 17-hidroxi-17-pentafluoroetil-estra-4-9(10)-dien-11-arilo como antagonistas de progesterona y procedimientos para su preparacion

Country Status (47)

Country Link
US (4) US20120149670A1 (es)
EP (4) EP3252069B1 (es)
JP (3) JP5795312B2 (es)
KR (2) KR101687853B1 (es)
CN (1) CN102482317B (es)
AR (1) AR077491A1 (es)
AU (1) AU2010275849B2 (es)
BR (1) BR112012001344B8 (es)
CA (1) CA2768407C (es)
CL (1) CL2012000166A1 (es)
CO (1) CO6491067A2 (es)
CR (2) CR20170091A (es)
CU (1) CU20120012A7 (es)
CY (3) CY1114260T1 (es)
DE (1) DE102009034362A1 (es)
DK (3) DK2623510T3 (es)
DO (2) DOP2012000015A (es)
EA (2) EA021946B1 (es)
EC (2) ECSP12011616A (es)
ES (3) ES2416461T3 (es)
GT (1) GT201200012A (es)
HN (1) HN2012000137A (es)
HR (3) HRP20130558T1 (es)
HU (2) HUE043757T2 (es)
IL (1) IL216967B (es)
IN (1) IN2012DN00598A (es)
JO (2) JO3009B1 (es)
LT (2) LT3252069T (es)
MA (1) MA33445B1 (es)
ME (2) ME03400B (es)
MX (2) MX2012000930A (es)
MY (1) MY179447A (es)
NO (1) NO2623510T3 (es)
NZ (2) NZ623417A (es)
PE (2) PE20170084A1 (es)
PL (3) PL2623510T3 (es)
PT (3) PT2623510T (es)
RS (1) RS52811B (es)
SG (3) SG10201811830PA (es)
SI (3) SI2623510T1 (es)
TN (1) TN2012000028A1 (es)
TR (1) TR201908600T4 (es)
TW (1) TWI505830B (es)
UA (1) UA106502C2 (es)
UY (1) UY32791A (es)
WO (1) WO2011009531A2 (es)
ZA (1) ZA201201222B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
SI2983671T1 (sl) * 2013-04-11 2020-06-30 Bayer Pharma Aktiengesellschaft Dozirna oblika antagonista receptorja progesterona
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
JP2018515551A (ja) 2015-05-18 2018-06-14 バイエル・ファルマ・アクティエンゲゼルシャフト 選択的プロゲステロン受容体モジュレーター(sprm)レジメン
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient
EP3701951A4 (en) * 2017-10-26 2020-09-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTAL SHAPE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND PROCESS FOR THEIR PRODUCTION
EP4486364A1 (en) 2022-03-01 2025-01-08 Altin Biosciences Corporation Crila® and egcg compositions for treatment of fibroids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2620707B1 (fr) 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
DK0411733T3 (da) 1989-08-04 1999-06-28 Schering Ag 11-beta-aryl-gona-4,9-dien-3-oner
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DK0792152T3 (da) 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Fremgangsmåder til svangerskabsforebyggelse
ATE194358T1 (de) 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU3344099A (en) 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de) 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
ATE344273T1 (de) 2000-09-18 2006-11-15 Applied Research Systems Verfahren zur herstellung von 21-hydroxy-6,19- oxidoprogesteron (21oh-6op)
DE10051609A1 (de) 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PL360151A1 (en) 2000-10-18 2004-09-06 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
PL366415A1 (en) 2000-10-18 2005-01-24 Schering Aktiengesellschaft Inhibition of the growth factor dependency of tumor cells
ES2290284T3 (es) * 2001-01-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft El uso de antigestagenos para inhibir la maduracion endometrial acelerada durante el tratamiento de infertilidad.
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DK1501859T3 (da) 2002-05-03 2006-03-06 Schering Ag 17 alfa-fluoralkyl- 11 beta-benzaldoxim-steroider, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse steroider samt deres anvendelse til fremstilling af lægemidler
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
MX2007000273A (es) 2004-07-09 2007-05-21 Population Council Inc Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
WO2006101009A1 (ja) 2005-03-18 2006-09-28 Hirose Engineering Co., Ltd. ナイルレッド系赤色発光化合物、及び発光素子
US20070105828A1 (en) 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20090075989A1 (en) * 2006-12-21 2009-03-19 Wolfgang Schwede Non-steroidal progesterone receptor modulators
CN101454150B (zh) 2007-03-01 2014-05-21 Prs地中海有限公司 耐uv的多层格室加固体系
EP2123279A1 (de) 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
SI3252069T1 (sl) 2019-06-28
PT2432798E (pt) 2013-06-28
SG10201811830PA (en) 2019-02-27
DOP2012000015A (es) 2016-04-15
EP3252069A1 (de) 2017-12-06
US20150342962A1 (en) 2015-12-03
PL2623510T3 (pl) 2018-02-28
GT201200012A (es) 2013-10-15
HN2012000137A (es) 2015-05-04
CY1119661T1 (el) 2018-04-04
HRP20191049T1 (hr) 2019-09-20
HK1171456A1 (en) 2013-03-28
EP2623510B1 (de) 2017-08-23
AU2010275849B2 (en) 2014-12-18
CU20120012A7 (es) 2012-07-31
EP2432798B1 (de) 2013-04-03
US20120094969A1 (en) 2012-04-19
SG10201404159VA (en) 2014-10-30
HUE037339T2 (hu) 2018-08-28
HRP20171805T1 (hr) 2017-12-29
LT3252069T (lt) 2019-06-10
IN2012DN00598A (es) 2015-06-12
ZA201201222B (en) 2022-11-30
AR077491A1 (es) 2011-08-31
KR20120046182A (ko) 2012-05-09
CN102482317B (zh) 2014-09-17
CR20120040A (es) 2012-03-12
HRP20130558T1 (hr) 2013-07-31
EA201301263A1 (ru) 2014-08-29
JP6130087B1 (ja) 2017-05-17
ECSP18047708A (es) 2018-06-30
ME03400B (me) 2020-01-20
BR112012001344B1 (pt) 2020-09-24
ES2648292T3 (es) 2017-12-29
DE102009034362A1 (de) 2011-01-27
UA106502C2 (uk) 2014-09-10
UY32791A (es) 2011-02-28
PT3252069T (pt) 2019-06-18
SG177519A1 (en) 2012-02-28
CY1114260T1 (el) 2016-08-31
KR101854059B1 (ko) 2018-05-02
AU2010275849A1 (en) 2012-02-02
EP3272763A1 (de) 2018-01-24
CN102482317A (zh) 2012-05-30
ES2416461T3 (es) 2013-08-01
US10155004B2 (en) 2018-12-18
PL3252069T3 (pl) 2019-09-30
EP2432798A2 (de) 2012-03-28
EP3252069B1 (de) 2019-04-03
PE20170084A1 (es) 2017-03-30
LT2623510T (lt) 2017-12-11
US9717739B2 (en) 2017-08-01
DK2432798T3 (da) 2013-07-01
EA201200121A1 (ru) 2012-07-30
JO3009B1 (ar) 2016-09-05
TWI505830B (zh) 2015-11-01
SI2623510T1 (sl) 2017-12-29
ECSP12011616A (es) 2012-02-29
ME01534B (me) 2014-04-20
BR112012001344B8 (pt) 2021-05-25
MA33445B1 (fr) 2012-07-03
MY179447A (en) 2020-11-06
NO2623510T3 (es) 2018-01-20
EA021946B1 (ru) 2015-10-30
TW201105331A (en) 2011-02-16
WO2011009531A3 (de) 2011-04-28
NZ597639A (en) 2014-04-30
EP2623510A1 (de) 2013-08-07
US20170202857A1 (en) 2017-07-20
WO2011009531A2 (de) 2011-01-27
TR201908600T4 (tr) 2019-07-22
CR20170091A (es) 2018-02-06
TN2012000028A1 (en) 2013-09-19
CA2768407A1 (en) 2011-01-27
JP2015178522A (ja) 2015-10-08
MX338217B (es) 2016-04-07
ES2730209T3 (es) 2019-11-08
MX2012000930A (es) 2012-03-26
IL216967B (en) 2018-06-28
BR112012001344A2 (pt) 2016-03-15
SI2432798T1 (sl) 2013-08-30
US8278469B2 (en) 2012-10-02
KR20160093110A (ko) 2016-08-05
JP2012533575A (ja) 2012-12-27
NZ623417A (en) 2015-10-30
EA025150B1 (ru) 2016-11-30
CU24080B1 (es) 2015-03-30
PT2623510T (pt) 2017-11-24
CY1121926T1 (el) 2020-10-14
CA2768407C (en) 2017-10-24
DK3252069T3 (da) 2019-06-24
JO3732B1 (ar) 2021-01-31
PL2432798T3 (pl) 2013-08-30
DK2623510T3 (en) 2017-12-04
CL2012000166A1 (es) 2012-08-31
RS52811B (sr) 2013-10-31
DOP2015000276A (es) 2018-04-15
US20120149670A1 (en) 2012-06-14
HUE043757T2 (hu) 2019-09-30
JP2017105813A (ja) 2017-06-15
KR101687853B1 (ko) 2016-12-19
CO6491067A2 (es) 2012-07-31
IL216967A0 (en) 2012-02-29
JP5795312B2 (ja) 2015-10-14

Similar Documents

Publication Publication Date Title
PE20121085A1 (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
GEP201706728B (en) Noxious organism control agent
NO20092004L (no) 2-[L-fenyl-5-hydroksy-4-alfa-metyl-heksahydrosyklopenta[f]indazol-5-yl]etylfenylderivater som glukokortikoidreseptorligandere
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
PE20160540A1 (es) Inhibidores de bromodominios
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
CR10034A (es) Derivados de oxadiazol
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
MY177250A (en) Novel nicotinamide derivative or salt thereof
IN2012DN01325A (es)
UY31463A1 (es) Inhibidores de péptido desformilasa
RU2015117251A (ru) Новые соединения
RU2012146777A (ru) Макроциклические ингибиторы интегразы
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
DE602006011609D1 (de) Organische verbindungen zur behandlung entzündlicher oder allergischer leiden
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
PE20141554A1 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparacion, preparados farmaceuticos que los contienen, asi como su uso para la preparacion de medicamentos
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
UY33150A (es) Compuestos carboxamida y su uso como inhibidores v de calpaína
PE20091847A1 (es) Derivados de piridil-ptolinamida como antagonistas de receptores nk1

Legal Events

Date Code Title Description
FG Grant, registration